• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Strive Health Scores $166M to Scale Value-Based Kidney Care

Share:

June 6, 2023

Denver-based kidney care company Strive Health has raised $166 million in a Series C funding round led by NEA and CVS Health Ventures. The company offers a value-based care platform that integrates patient data for chronic kidney disease and end-stage renal disease, allowing for disease progression identification and predictions. The funds will be used to expand partnerships with payors, physicians, and health systems, as well as to refine the care model, enhance technology delivery, and scale the business across the United States. Strive Health previously raised $140 million in a Series B funding round in 2021.

Kidney care company Strive Health scored a whopping $166 million in Series C funding led by NEA alongside strategic investor CVS Health Ventures.

Existing investors CapitalG (Alphabet), Town Hall Ventures, Redpoint, Echo Health Ventures and Ascension Ventures also participated in the round.

WHAT IT DOES

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The Denver-based company offers a value-based care platform that integrates chronic kidney disease and end-stage renal disease patient data from various systems into one platform. The technology was designed to identify disease progression and make predictions about a patient’s condition.

The company also offers patients support through kidney transplants and dialysis. Patients access dialysis through traditional methods or home hemodialysis through Strive’s collaboration with Outset Medical.

The funds will be used to expand partnerships with Medicare, commercial and Medicare Advantage payors, physicians and health systems.

“With the new funding, we’ll continue to grow in new markets and scale in our current markets as those become more dense. We’ll do this by refining our care model, enhancing our technology delivery and scaling the business across the U.S.,” Chris Riopelle, CEO and cofounder of Strive, told MobiHealthNews in an email.

“For the next phase of company growth, we’ll also continue to attract and retain our great employees as this is the building block of what makes the company successful. We know we can only take care of other people well when we take care of our own people, or what we call Strivers, first.”

MARKET SNAPSHOT

In 2021, Strive Health garnered $140 million in Series B funding, led by Alphabet’s growth fund CapitalG, which was expected to give the company “unique access” to Google and Alphabet assets.

Since then, the company’s partnered with nephrology group Southern California Kidney Consultants and not-for-profit Catholic healthcare system Trinity Health to improve kidney care for patients.

Another company in the kidney care space is tech-backed chronic kidney disease and end-stage renal disease management company Monogram Health. Monogram scored a whopping $375 million in growth funding in January, just two years after it closed a $160 million Series B funding round,

Source: MobihealthNews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Vertex Shells Out $950 Million To Acquire A Company Working On A Diabetes CureVertex Shells Out $950 Million To Acquire A Company Working On A Diabetes Cure
  • Genesis Biotechnology Group Acquires Nedp to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (gd3)Genesis Biotechnology Group Acquires Nedp to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (gd3)
  • Validic Integrates Medical Device Data with Wellframe AppValidic Integrates Medical Device Data with Wellframe App
  • Blockchain prototype aims to speed revenue cycle transactionsBlockchain prototype aims to speed revenue cycle transactions
  • THREAD Lands $50M for Decentralized Clinical Trial Research PlatformTHREAD Lands $50M for Decentralized Clinical Trial Research Platform
  • XRHealth to Launch Virtual Reality Telehealth Clinic in Israel In NovemberXRHealth to Launch Virtual Reality Telehealth Clinic in Israel In November
  • Rite Aid Integrates NarxCare Analytics Directly into its Pharmacist’s Workflow in 12 StatesRite Aid Integrates NarxCare Analytics Directly into its Pharmacist’s Workflow in 12 States
  • Roche Bolsters Diagnostics Pipeline with $1.8 Billion Buy of GenMarkRoche Bolsters Diagnostics Pipeline with $1.8 Billion Buy of GenMark

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications